Finerenone, sold under the brand name Kerendia, is already approved by the FDA for reducing heart and kidney risks in patients with chronic kidney disease (CKD) and type 2 diabetes. Bayer plans on presenting the new data in full at ESC Congress 2024 in London.
CVRx has now received improved outpatient and inpatient reimbursements for its implantable heart failure device in the last 12 months. The company's president says these updates will help more patients gain access to the Barostim technology.
Bharath Krishnamurthy, a director of health policy and analytics at the American Hospital Association, explains the financial impact of current healthcare staffing shortages.
The drugmaker argues that the FDA's recent approval of a generic version of Entresto should not be allowed for multiple reasons. Novartis sent multiple requests to the agency hoping to stop the approval, but the FDA denied each one.
The new medical device correction only includes a select number of devices. Abbott said they produce inaccurate readings, putting patient health at risk.
The diabetes drug, sold by Eli Lilly and Company under the brand names Zepbound and Mounjaro, was associated with better outcomes, improved symptoms and more significant weight loss than a placebo.
Echocardiography vs CT for Prediction of Newly Created LVOT Area: (A-D) Newly created left ventricular outflow tract (neo-LVOT) assessment by echocardiography and (E-H) CT, both before and after valve implantation. Images courtesy of Bartkowiak et al., JACC: Cardiovascular Imaging.
LVOT obstruction after TMVR remains a significant concern among structural heart cardiologists. Predicting the risk of LVOT obstruction typically requires CT, which comes with certain disadvantages compared to other imaging options.
